Umifenovir
Umifenovir: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. Drug interactions
- 12. Analogs
- 13. Terms and conditions of storage
- 14. Terms of dispensing from pharmacies
- 15. Reviews
- 16. Price in pharmacies
Latin name: Umifenovir
ATX code: J05AX13
Active ingredient: umifenovir (Umifenovir)
Manufacturer: Ozone, LLC (Russia)
Description and photo update: 2020-04-03
Prices in pharmacies: from 128 rubles.
Buy
Umifenovir is an antiviral agent.
Release form and composition
The drug is produced in the form of capsules: gelatinous, opaque, solid, size No. 2, body - yellow (dosage 50 mg) or white (dosage 100 mg) color, lid - yellow; contents of capsules: a mixture of granules and powder from white to white with a beige or green-yellow tint; there may be lumps of granules and powder that disintegrate when pressed (5 or 10 pieces in a blister strip or 10, 20, 30, 40, 50, 80 or 100 pieces in a PET / polypropylene jar, in a cardboard box 1-6, 8 or 10 blisters or 1 can and instructions for the use of Umifenovir).
Composition for 1 capsule:
- active substance: umifenovir hydrochloride monohydrate - 51.75 or 103.5 mg, which is equivalent to umifenovir hydrochloride in the amount of 50 or 100 mg, respectively;
- additional components: croscarmellose sodium, povidone-K25, microcrystalline cellulose, potato starch, magnesium stearate, colloidal silicon dioxide;
- shell: capsule body - titanium dioxide, gelatin; additionally for a dosage of 50 mg - dyes quinoline yellow and sunset yellow; capsule cap - gelatin, titanium dioxide, quinoline yellow and sunset yellow dyes.
Pharmacological properties
Pharmacodynamics
Umifenovir is an antiviral agent that in vitro specifically suppresses influenza A and B viruses (Influenza virus A, B), including such highly pathogenic subtypes as A (H5N1) and A (H1N1) pdm09, and other viruses that cause acute respiratory viral infections (ARVI), including coronavirus (Coronavirus), leading to severe acute respiratory syndrome (SARS), adenovirus (Adenovirus), rhinovirus (Rhinovirus), parainfluenza virus (Paramyxovirus), respiratory syncytial virus (Pneumovirus). According to the mechanism of action, the active substance belongs to the group of fusion inhibitors (fusion), interacts with the hemagglutinin of the virus and prevents the fusion of the cell membrane and the lipid membrane of the virus.
The tool exhibits a moderate immunomodulatory effect, enhances the body's resistance to viral lesions. Demonstrates interferon-inducing activity - in the course of studies on mice, the induction of interferons was recorded 16 hours after administration, and high titers of interferons remained in the blood for up to 48 hours.
The drug initiates the course of cellular and humoral reactions of immunity: it increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4), does not affect the content of T-suppressors (CD8), normalizes the immunoregulatory index, promotes activating the phagocytic function of macrophages and increasing the number of natural killer cells (NK cells).
Against the background of viral infections, the therapeutic effect of umifenovir is manifested in a decrease in the duration and severity of the disease and its main symptoms, as well as in a decrease in the incidence of complications caused by a viral infection and exacerbations of chronic bacterial diseases. In the treatment of acute respiratory viral infections, including influenza, in the course of a clinical study, it was found that the effect of umifenovir in adult patients is especially pronounced in the acute phase of the disease and manifests itself in the form of a reduction in the period of resolution of symptoms of the disease, a decrease in the severity of manifestations of the lesion, and a decrease in the time for virus elimination.
The use of the active substance provides a higher frequency of symptom relief on the third day of treatment compared to placebo. 60 hours after the start of the course, the resolution of all flu symptoms is more than 5 times higher than in the placebo group. A significant effect of the drug on the rate of elimination of the influenza virus was noted, which leads to a decrease in the frequency of detection of the RNA virus on the fourth day.
Umifenovir is a low-toxic drug - a half-lethal dose (LD 50)> 4 g / kg. When used orally in recommended doses, it does not have any negative effect on the human body.
Pharmacokinetics
The active substance is intensively absorbed and distributed throughout the organs and tissues of the body. In blood plasma, its maximum concentration (C max) when taken orally at a dose of 50 mg is observed after 1.2 hours, at a dose of 100 mg - after 1.5 hours. The process of biotransformation takes place in the liver, approximately 40% of the agent is excreted unchanged mainly with bile (38.9%) and in an insignificant volume - with urine (0.12%). The half-life is 17-21 hours, during the first day 90% of the dose taken is eliminated.
Indications for use
- recurrent infection caused by herpes viruses (combination therapy);
- influenza A and B and other acute respiratory viral infections (prevention and treatment);
- postoperative infectious complications (prevention).
Contraindications
Absolute:
- I trimester of pregnancy, breastfeeding;
- children under 3 years old; up to 6 years - for capsules with a dosage of 100 mg;
- hypersensitivity to any component of the drug.
Antiviral agent should be taken with extreme caution in the II – III trimesters of pregnancy.
Umifenovir, instructions for use: method and dosage
Umifenovir capsules are taken orally, before meals.
You should start taking the drug from the moment the first symptoms of SARS appear, including influenza, preferably no later than 3 days from the onset of the disease.
Recommended single doses (depending on the patient's age):
- children from 3 to 6 years old - 50 mg;
- children from 6 to 12 years old - 100 mg (2 capsules of 50 mg or 1 capsule of 100 mg);
- adolescents from 12 years old and adults - 200 mg (4 capsules of 50 mg or 2 capsules of 100 mg).
The recommended frequency and duration of taking Umifenovir for children and adults (in a single dose):
- nonspecific prophylaxis: during an epidemic of acute respiratory viral infections, including influenza, - 2 times a week, course - 21 days; with direct contact with patients with acute respiratory viral infections - 1 time / day, course - 10-14 days;
- flu and other acute respiratory viral infections (treatment): 4 times / day (every 6 hours), course - 5 days;
- recurrent herpetic infection (as part of complex therapy): 4 times / day (every 6 hours) for 5-7 days, then - 2 times a week for 28 days;
- postoperative infectious complications (for prophylaxis): 1 time / day 2 days before surgery, then on the 2nd and 5th days after surgery.
Side effects
Umifenovir is generally well tolerated. Adverse events are rare, usually temporary, and mild / moderate.
In rare cases (with a frequency of at least 1/10 000, but less than 1/1000), allergic reactions may occur.
If these reactions worsen or any other side effects develop, you must inform your doctor.
Overdose
There is no information on an overdose of Umifenovir.
special instructions
The drug should be used according to the recommended dosage regimen.
With influenza and other acute respiratory viral infections, in the case when, after treatment with the drug for 3 days, the severity of the symptoms of the disease does not decrease (including body temperature 38 ° C and above), it is required to contact a specialist to assess the feasibility of using this antiviral agent.
If the next dose was missed, this dose should be taken as early as possible and then continue the course as usual.
Influence on the ability to drive vehicles and complex mechanisms
Umifenovir does not have central neurotropic activity and can be used for prophylactic / therapeutic purposes in patients driving vehicles and other complex moving mechanisms.
Application during pregnancy and lactation
In the course of preclinical studies in animals, the harmful effects of the drug on pregnancy, embryo / fetal development, childbirth and postnatal development were not detected.
The use of the drug in the first trimester of pregnancy is contraindicated. The use of Umifenovir capsules in the II and III trimesters of pregnancy is allowed only for the prevention / treatment of influenza in cases where the expected benefit for the woman significantly exceeds the potential threat to the fetus. Pregnant women should take the drug only as directed by a doctor.
It has not been established whether the agent penetrates into breast milk in women. If the use of Umifenovir is necessary during lactation, you need to stop breastfeeding.
Pediatric use
Umifenovir is contraindicated in pediatric patients under 3 years of age (capsules with a dosage of 50 mg), under 6 years of age (capsules with a dosage of 100 mg). Therefore, children aged 3 to 6 years are prescribed umifenovir in a single dose not exceeding 50 mg.
Drug interactions
Special clinical studies to study the interaction of umifenovir with other drugs / drugs have not been conducted.
When used with other drugs, no negative effects have been reported.
No undesirable interaction of the drug with mucolytic, antipyretic and local vasoconstrictor agents was found in a clinical study.
Analogs
Umifenovir's analogues are Arpeflu, Aflyudol, Arbidol, Arbidol Maximum, etc.
Terms and conditions of storage
Store out of the reach of children at a temperature not exceeding 25 ° C.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Available without a prescription.
Reviews about Umifenovir
Currently, there are no reviews on Umifenovir on specialized sites, according to which it would be possible to objectively assess the therapeutic effect and disadvantages of an antiviral agent.
Price for Umifenovir in pharmacies
There is no reliable information on the price of Umifenovir, since the drug is not currently available in the pharmacy chain. The cost of an analogue of the drug, Afludol, in the form of film-coated tablets, can be: per pack of 20 pcs. 50 mg - 85–160 rubles, per pack of 20 pcs. 100 mg - 257–286 rubles, per package of 40 pcs. 50 mg each - from 350 rubles, per pack of 40 pcs. 100 mg each - from 578 rubles.
Umifenovir: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Umifenovir capsules 50mg 10pcs RUB 128 Buy |
|
Umifenovir 50 mg capsule 20 pcs. 227 r Buy |
|
Umifenovir 100 mg capsule 20 pcs. 398 RUB Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
